For patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic disease, treatment commonly consists of endocrine therapy in combination with targeted agents such as cyclin-dependent kinase (CDK) 4/6, PI3K, or AKT inhibitors. Here, NR4A1 is linked to metastatic neoplasm.